Current Share Price and Valuation (as of 2025-11-21)
- Share price: KRW 1,852 (up +15.5% from the previous day)
- Intraday range: KRW 1,530 ~ 2,055
- 52-week range: KRW 949 ~ 2,170
- Market capitalization: about KRW 81.9 billion
- 1-year return: about +68%
- PER: about 15–18x (around 15.6x / 18.6x depending on the site)
- PBR: about 1.25–1.3x
- Dividend yield: about 0.38%
Overall, it feels like:
“A small-cap value stock that does generate net profit (low PBR) + with a bit of a cold-chain/bio theme premium on top”
(for a bio-theme name, the valuation is not extremely aggressive).
Company and Business Structure
- Founded in 1988, listed on KOSDAQ in 2007
- A bio equipment / cold-chain equipment company that manufactures:
- Ultra-low temperature freezers
- Freeze dryers
- Plant-type (large-scale) freeze dryers, etc.
- Supplies equipment to biotech research labs, hospitals, national research institutes, pharmaceutical companies, and food companies
- Acts as an infrastructure provider for bio-pharmaceutical cold chain, including:
- Ultra-low temperature equipment below –70°C
- Storage for vaccines, cell therapies, anticancer drugs, etc.
→ So it is not a “bio drug development company”, but rather
a company that sells freezing and freeze-drying equipment needed to store and distribute vaccines, obesity treatments, and biosimilars.
Recent Earnings and Financial Trends
① Last 3 Years: Period of Revenue Decline
Annual revenue:
- 2021: KRW 24.4 billion
- 2022: KRW 20.4 billion
- 2023: KRW 16.4 billion
- 2024: KRW 10.8 billion
→ Three consecutive years of revenue decline, and the order backlog shrank from KRW 9.7 billion → 3.6 billion.
So up to 2024, the market’s image was:
“A cold-chain stock that lost steam after the COVID special demand ended.”
② 2025: Signs of a Turnaround
Half-year and Q3 results
- First half of 2025 (separate basis)
- Revenue: +25.9% YoY
- Operating profit: +115% YoY
- Net profit: +2.3% YoY
- Q3 2025 (standalone quarter)
- Revenue: KRW 4.9 billion (+86% YoY, +37% QoQ)
- Operating profit: KRW 1.9 billion (+408% YoY, +70% QoQ)
- Net profit: KRW 1.9 billion (+265% YoY, +159% QoQ)
→ On a quarterly basis, this marks a phase where growth and profit improvement have started to show quite strongly.
③ Increase in Order Backlog
- Order backlog at the end of 2021: KRW 9.7 billion → shrank to KRW 3.6 billion by the end of 2024.
- However, in the first half of 2025, the order backlog rose to KRW 6.9 billion,
a +92% increase compared to the end of last year. - In particular, the order backlog for large freeze dryers (LP models)—which account for more than half of the company’s sales—
makes up about 87% of the total backlog.
→ Since orders are piling up mainly in its core products, this is being interpreted as a signal of potential revenue rebound in 2025–26.
④ Individual Contract News
- 2025-10-13: Public disclosure of a supply contract with Ildong Bioscience
for freeze dryers and ultra-low temperature freezers
(each worth KRW 900 million, roughly 8.3% of recent annual sales).
Situations like this—equipment supply contracts with bio/healthcare companies—
are appearing more frequently in news articles and regulatory disclosures.
Recent Share Price Movements & Themes
1. Representative Cold-Chain (Low-Temperature Logistics) Theme Stock
- Since the COVID era, the company has been categorized as a cold-chain-related stock,
- And recently, it has come back into the spotlight due to:
- Rising demand for obesity treatments and vaccines, and
- KGSP (Good Storage and Distribution Practices for pharmaceuticals; cold-chain requirements) issues.
2. Theme-Driven Spikes → Short-Term Overheating Designation
- During periods of strong cold-chain theme sentiment,
Ilshin Bio has had days where it surged +20–30%. - In May–June 2025, there were regulatory notices and designations of the stock as a
“short-term overheated issue” (subject to single-price auction trading for 3 sessions).
3. Performance Over the Past Year
- 1-year return: +68%
- 6-month return: also in the +50% range
So this is not in a “deep bottom box” zone; rather,
it has already experienced one big rally and is now in a pullback / re-rise phase.
Outlook – Key Points
(1) Positive Factors
1. Structural Demand for Cold-Chain / Bio Infrastructure
- The market for biopharmaceuticals that require low-temperature and ultra-low-temperature storage—
such as GLP-1 obesity treatments, vaccines, and cell therapies—is growing. - In Korea as well, regulations such as KGSP are being strengthened,
making cold-chain infrastructure legally more important.
→ This structure itself belongs to a mid- to long-term growth industry.
2. Possibility of an Earnings Turnaround
- After three years of declining revenue,
sales and profits started to return to a growth path in 2025. - The order backlog has increased noticeably compared to the past,
and the fact that most of it is in core large freeze dryers (LP models) is a positive sign.
3. Valuation Is Not at an Extremely Expensive Level
- A PER of 15–18x and PBR of 1.2–1.3x are,
for a KOSDAQ bio equipment / theme stock,
relatively reasonable valuations. - Of course, since the company’s net profit is volatile,
you can’t rely solely on PER, but
compared to pure bio platform names like ABL Bio / ABL
(with PBR in the dozens),
the burden is clearly lighter.
4. Financial Risk Is Not Very High
- Based on recent disclosures,
leverage ratios and liquidity indicators are not at alarmingly dangerous levels,
so it’s closer to the category of:
“Unlike some bios, it is not currently in a situation with immediate delisting/watchlist risk,”
though ongoing monitoring is still necessary.
(2) Risks and Points of Caution
1. Small-Cap Stock
- With a market cap in the KRW 80 billion range and quarterly sales around KRW 4–5 billion,
this is not the type of stock that large institutions can comfortably hold in size for a long time. - Liquidity is thin, so based on themes/news, the share price can move 10–20% in a single day.
2. Project / Order-Dependent Business Structure
- In years when orders come in strongly, results can spike sharply,
- But when there is an order gap, revenue and profit can drop sharply,
which is a typical volatility pattern for a “contract-based equipment business.”
3. Theme-Driven Overheating and Correction Risk
- Depending on news related to cold chain, obesity treatments, and vaccines,
the stock can follow a “theme spike → short-term overheating designation → correction” pattern repeatedly. - The share price can be front-run by keywords like “obesity treatment, vaccine, COVID resurgence”
more than by fundamentals such as actual earnings and orders,
so if the theme cools down, the pullback can also be large.
4. Limited Analyst Coverage and Information
- There are almost no major securities firm reports / consensus on this stock,
so there is a lack of “guidance” such as future earnings forecasts and target prices.
This means it can be more vulnerable to information asymmetry and rumor-driven trading.
Summary from an Individual Investor’s Perspective
Character:
“A small-cap cold-chain/bio infrastructure stock
- at the early stage of an earnings turnaround
- with high theme-driven volatility.”
Short Term (a Few Weeks to 1 Year)
Share price catalysts:
- News related to cold chain, obesity treatments, vaccines
- Additional supply contracts / order announcements
- Quarterly earnings releases (trends in sales, profits, and order backlog)
Risks of similar magnitude:
- The stock is already up over +60% in a year,
- So there is a real possibility of a “short-term spike → short-term overheating designation → correction” pattern repeating.
➡ It is closer to a “trading stock that rides short-term waves based on themes/news”,
and it’s more realistic to set explicit numerical buy/sell rules (stop-loss / target price) before entering.
Medium to Long Term (3–5 Years)
Bull (strong) scenario
- Growing demand for cold-chain/bio infrastructure →
annual revenue recovers and grows back to the KRW 20 billion+ level - Order backlog continues to expand, and long-term supply partnerships grow
with major domestic/global pharma and biotech companies - Profits stabilize, and at a PER of 10–15x the company establishes itself as
a “cold-chain infrastructure stock that pays dividends and delivers earnings growth”
→ In this case, there is upside potential even at the current valuation level over the medium to long term.
Neutral scenario
- Earnings keep repeating a pattern of improving and then weakening,
but the long-term trend is gentle growth / broad trading range. - The stock pops during theme-driven rallies, and is sluggish otherwise.
Bear scenario
- If the heat around cold-chain / vaccine / obesity treatment themes fades, or
- Orders and earnings decline again and the company re-enters a revenue contraction phase like before,
→ The perception that it was “overheated at the peak of the theme” could spread,
leading to valuation compression (multiple contraction).